Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
Pacira Pharmaceuticals (NASDAQ: PCRX) shares are down 15% at 12:00 p.m. EDT today following word that its pain medicine Exparel didn't perform as well as hoped in key phase 3 studies.
Pacira Pharmaceuticals already markets the surgical-pain medicine Exparel, and its sales have been growing quickly as doctors embrace ways to control pain that may reduce a patient's need for rescue pain medications, like opioids.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Pacira Pharmaceuticals Stock
€18.00
-2.170%
With 22 Buy predictions and not a single Sell prediction Pacira Pharmaceuticals is an absolute favorite of our community.
With a target price of 41 € there is potential for a 127.78% increase which would mean more than doubling the current price of 18.0 € for Pacira Pharmaceuticals.
